VMD
Viemed Healthcare, Inc.Price & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $14.3M | the quarter ended March 31, 2026 | — |
|
|
|||
| Free cash flow non-GAAP | $2.6M | the quarter ended March 31, 2026 | — |
| Free cash flow (trailing twelve months) non-GAAP | $36.3M | trailing twelve months ended March 31, 2026 | — |
| Net cash provided by operating activities | $8.1M | the quarter ended March 31, 2026 | — |
| Net cash provided by operating activities (trailing twelve months) | $57.1M | trailing twelve months ended March 31, 2026 | — |
| PAP therapy patient count | 35,938 | as of March 31, 2026 | +4.1% |
|
|
|||
| Sleep resupply patient count | 33,661 | as of March 31, 2026 | -7.9% |
|
|
|||
| Ventilator patient count | 12,089 | as of March 31, 2026 | -1.4% |
|
|
|||
| employees | 1,387 | Q1 2026 call | — |
| PAP therapy patients | 35,938 | Q1 2026 call | — |
| ventilator setups | 759 | March 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VMD
this stock
Viemed Healthcare, Inc.
|
$462.73M | +62.4% | +20.5% | 32.6 | 1.2% |
|
ABT
Abbott Laboratories
|
$166.94B | -23.1% | +5.7% | 26.9 | 1.3% |
|
SYK
Stryker Corp
|
$126.41B | -5.9% | +11.2% | 38.2 | 1.6% |
|
MDT
Medtronic plc
|
$107.31B | -12.0% | +8.4% | 22.5 | 1.4% |
|
BSX
Boston Scientific Corp
|
$67.33B | -52.5% | +5.5% | 19.0 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VMD | +6.0% | +21.1% | +65.3% | +5.9% | +62.5% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +5.1% | +19.7% | +57.8% | +5.8% | +52.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.